Skip to content
Bored Studies
RecruitingPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Eli Lilly and Company · NCT07392190

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
900
US sites recruiting
56
Study start
February 10, 2026
Record last updated
September 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.

Participation in the study will last about 80 weeks.

Being studied: Eloralintide; Placebo

Conditions: Overweight; Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Are on stable incretin therapy at screening
  • With persistent obesity or overweight defined as:
  • ≥30 kg/m2 OR
  • ≥27 kg/m2 with at least one existing obesity related complication at screening:
  • hypertension
  • dyslipidemia
  • obstructive sleep apnea
  • cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
  • type 2 diabetes
  • Have a stable body weight (\<5% body weight change) at screening

Exclusion Criteria

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have type 1 diabetes
  • Have taken any of the following antihyperglycemic medications within 90 days before screening:
  • dipeptidyl peptidase-4 (DPP-4) inhibitors
  • amylin analogs
  • insulin
  • Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Recruiting US locations

  • Birmingham Clinical Research

    Birmingham, AL 35209

    Site contact: 205-870-4343

  • RIO Clinical Trials - Phoenix

    Phoenix, AZ 85016

    Site contact: 480-966-7882

  • Headlands Research - Scottsdale

    Scottsdale, AZ 85260

    Site contact: 480-725-8708

  • Novak Clinical Research - Tucson - North La Cholla Boulevard

    Tucson, AZ 85741

    Site contact: Thili Kulatilake

  • Irvine Clinical Research

    Irvine, CA 92614

    Site contact: 949-753-1663

  • Scripps Whittier Diabetes Institute

    La Jolla, CA 92037

    Site contact: 858-824-5352

  • Peninsula Research Associates

    Rolling Hills Estates, CA 90274

    Site contact: 310-265-1623

  • Artemis Institute for Clinical Research

    San Diego, CA 92123

    Site contact: 858-278-3647

  • Southern California Clinical Research

    Santa Ana, CA 92701

    Site contact: 714-474-2173

  • University Clinical Investigators, Inc.

    Tustin, CA 92780

    Site contact: 714-734-7944

  • New England Research Associates, LLC

    Bridgeport, CT 06606

    Site contact: 203-374-9816

  • Yale University School of Medicine

    New Haven, CT 06519

    Site contact: 203-785-7421

  • Chase Medical Research, LLC

    Waterbury, CT 06708

    Site contact: 203-419-4420

  • JEM Research Institute

    Atlantis, FL 33462

    Site contact: 561-968-2933

  • AMR Clinical

    Doral, FL 33172

    Site contact: Abid Chaudhry

  • Northeast Research Institute (NERI)

    Fleming Island, FL 32003

    Site contact: 904-541-8225

  • Jacksonville Center for Clinical Research

    Jacksonville, FL 32216

    Site contact: 904-730-0101

  • New Horizon Research Center

    Miami, FL 33165

    Site contact: 305-226-3933

  • St Johns Center for Clinical Research

    Saint Augustine, FL 32086

    Site contact: 904-209-0043

  • Metabolic Research Institute, Inc.

    West Palm Beach, FL 33401

    Site contact: 561-802-3060

  • Teak Research Consults - Dunwoody

    Dunwoody, GA 30338

    Site contact: 470-403-4755

  • Center for Advanced Research & Education

    Gainesville, GA 30501

    Site contact: 770-534-5154

  • Clinical Research Atlanta

    Stockbridge, GA 30281

    Site contact: 770-507-6867

  • Family First Medical Center

    Idaho Falls, ID 83404

    Site contact: 208-552-7700

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, IL 60640

    Site contact: 773-275-3500 Ext 162

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, IA 50266

    Site contact: Amy Keller

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, KS 66606

    Site contact: 785-354-9591

  • AMR Clinical

    Lexington, KY 40509

    Site contact: Peter Akpunonu

  • IMA Clinical Research Monroe - Armand

    Monroe, LA 71201

    Site contact: Clinton Guillory

  • Centennial Medical Group

    Columbia, MD 21045

    Site contact: 410-730-3399

  • Brigham and Women's Hospital Diabetes Program

    Boston, MA 02115

    Site contact: 617-732-4245

  • MedVadis Research Corporation

    Waltham, MA 02451

    Site contact: 617-744-1310

  • Great Lakes Research Institute

    Southfield, MI 48075

    Site contact: 248-864-5242

  • Revive Research Institute, Inc.

    Southfield, MI 48075

    Site contact: 248-829-3103

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, MI 48098

    Site contact: 248-312-0025

  • Clinical Research Professionals

    Chesterfield, MO 63005

    Site contact: 636-220-1200

  • NYU Langone Health

    New York, NY 10016

    Site contact: 212-263-3166

  • Weill Cornell Medical College

    New York, NY 10021

    Site contact: 646-962-2111

  • IMA Clinical Research Manhattan

    New York, NY 10036

    Site contact: Eli Shalenberg

  • University of North Carolina Medical Center

    Chapel Hill, NC 27514

    Site contact: 984-974-3004

  • Medication Management

    Greensboro, NC 27401

    Site contact: 336-763-6968

  • Carteret Medical Group

    Morehead City, NC 28557

    Site contact: 252-499-8623

  • Accellacare - Wilmington - 1917 Tradd Court

    Wilmington, NC 28401

    Site contact: 910-799-5500

  • CTI Clinical Research Center

    Cincinnati, OH 45212

    Site contact: 513-721-3868

  • Care Access - Lima

    Lima, OH 45805

    Site contact: Jimmy Alele

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

    Pittsburgh, PA 15236

    Site contact: 412-650-6155

  • UT Southwestern Medical Center

    Dallas, TX 75390

    Site contact: Amy Shah

  • Juno Research

    Houston, TX 77040

    Site contact: 713-779-5494

  • Activian Clinical Research

    Kingwood, TX 77339

    Site contact: 832-969-3401

  • Texas Valley Clinical Research (TVCR) - Mission

    Mission, TX 78572

    Site contact: Alejandro Gonzalez Campos

  • Synergy Groups Medical LLC - Missouri City

    Missouri City, TX 77459

    Site contact: 832-532-4210

  • IMA Clinical Research San Antonio

    San Antonio, TX 78229

    Site contact: 210-692-7157

  • Endeavor Clinical Trials

    San Antonio, TX 78240

    Site contact: 518-428-6859

  • Consano Clinical Research, LLC

    Shavano Park, TX 78231

    Site contact: 210-545-4900

  • Texas Valley Clinical Research

    Weslaco, TX 78596

    Site contact: 956-431-8090

  • Medrasa Clinical Research

    Wylie, TX 75098

    Site contact: 469-449-3645

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Alabama →
A Study of Eloralintide (LY3841136) in Participants With… (NCT07392190) | Bored Studies